Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Pritesh Patel, MD, Vitalyi Senyuk, PhD, Natalie S. Rodriguez, MS, Dolores Mahmud, PhD, Annie Lee Oh, MD, Nadim Mahmud, MBBS, PhD, Giovanni Barosi, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2018-99-119497

Published: 2018

Journal Articles

Combined Nanoparticle Delivery of PARP and DNA-PK Inhibition for Multiple Myeloma

Pritesh Patel, MB, CHB, Santosh Misra, PhD, Natalie S. Rodriguez, MS, Gururaja Vulugundam, PhD, Annie L. Oh, MD, Vitalyi Senyuk, PhD, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Dipanjan Pan

Blood (2017) 130 (Supplement 1): 1809.

https://doi.org/10.1182/blood.V130.Suppl_1.1809.1809

Published: 2017

Journal Articles

The Cytotoxic Effect of the PARP Inhibitor ABT-888 on Myeloproliferative Neoplasms

Pritesh R. Patel, MB, ChB, Vitalyi Senyuk, PhD, Elisa Bonetti, PhD, Dolores Mahmud, PhD, Shrihari S. Kadkol, MD PhD, Annie L. Oh, MD, Nadim Mahmud, MD PhD, Damiano Rondelli, MD

Blood (2016) 128 (22): 4276.

https://doi.org/10.1182/blood.V128.22.4276.4276

Published: 2016

Journal Articles

C75 Fatty Acid Synthesis (FAS) Inhibitor Has Potent Immunosuppressive Activity

Vitalyi Senyuk, PhD, Dolores Mahmud, PhD, Annie L. Oh, MD, Pritesh R. Patel, MD, Damiano Rondelli, MD

Blood (2016) 128 (22): 2156.

https://doi.org/10.1182/blood.V128.22.2156.2156

Published: 2016

Journal Articles

In-Vitro and in-Vivo Synergistic Effect of Melphalan and Dual DNA Repair Inhibition in Multiple Myeloma

Pritesh R. Patel, MB, ChB, Annie L. Oh, MD, Vitalyi Senyuk, PhD, Dolores Mahmud, PhD, Nadim Mahmud, MD PhD, Damiano Rondelli, MD

Blood (2016) 128 (22): 3301.

https://doi.org/10.1182/blood.V128.22.3301.3301

Published: 2016

Journal Articles

Dual DNA Damage Repair Inhibition Synergizes with Alkylator Chemotherapy for Myeloma and Acute Leukemia

Pritesh R. Patel, MB, ChB, Vitalyi Senyuk, PhD, Dolores Mahmud, PhD, Annie L. Oh, MD, Damiano Rondelli, MD

Blood (2015) 126 (23): 2053.

https://doi.org/10.1182/blood.V126.23.2053.2053

Published: 2015

Journal Articles

Preclinical Study for the Use of Abatacept to Prevent Rejection of Allogeneic CD34+ Cells in a Xenograft Model

Annie L. Oh, MD, Dolores Mahmud, PhD, Vitalyi Senyuk, PhD, Elisa Bonetti, PhD, Nadim Mahmud, MD PhD, Pritesh R. Patel, MB, ChB, Damiano Rondelli, MD

Blood (2015) 126 (23): 4271.

https://doi.org/10.1182/blood.V126.23.4271.4271

Published: 2015

Journal Articles

A Critical Role of Mir-9 in Myelopoesis and EVI1-Induced Leukemogenesis.

Vitalyi Senyuk, PhD, Yunyuan Zhang, Yang Liu, Ming Ming, PhD, Jianjun Chen, PhD, Janet D. Rowley, MD, Giuseppina Nucifora, PhD, Zhijian Qian, PhD

Blood (2012) 120 (21): 2332.

https://doi.org/10.1182/blood.V120.21.2332.2332

Published: 2012

Journal Articles

Methylation and Silencing of miRNA-124 In Hematopoietic Cells by EVI1

Vitalyi Senyuk, PhD, Kavitha Premanand, Peng Xu, MD, PhD, Francesca Cattaneo, Jerome Dickstein, Giuseppina Nucifora

Blood (2010) 116 (21): 2476.

https://doi.org/10.1182/blood.V116.21.2476.2476

Published: 2010

Journal Articles

Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia

Ciro R Rinaldi, MD, Paola Rinaldi, Adele Alagia, Marica Gemei, Vitalyi Senyuk, PhD, Nicola Esposito, Fabio Formiggini, Vincenzo Martinelli, Anthony R. Green, PhD, FRCP, FRCPath, Giuseppina Nucifora, Fabrizio Pane, MD

Blood (2010) 116 (21): 4089.

https://doi.org/10.1182/blood.V116.21.4089.4089

Published: 2010

Journal Articles

EVI1 Interacts with and Represses RUNX1: A Novel Mechanism of Deregulated Hematopoiesis in EVI1-Positive Hematopoietic Cells.

Vitalyi Senyuk, PhD, Kislay K. Sinha, PhD, Sastry Yanamandra, PhD, Giuseppina Nucifora, PhD

Blood (2006) 108 (11): 1190.

https://doi.org/10.1182/blood.V108.11.1190.1190

Published: 2006

Journal Articles

AML1/MDS1/EVI1 Induces Essential Thrombocythemia in Mice Independently of Jak2 Mutations.

Vitalyi Senyuk, PhD, Donglan Li, MD, PhD, Raffaella Fazzina, Francesca Cattaneo, PhD, Ciro R. Rinaldi, MD, Jerome Dickstein, MD, PhD, Giuseppina Nucifora, PhD

Blood (2006) 108 (11): 3622.

https://doi.org/10.1182/blood.V108.11.3622.3622

Published: 2006

NARROW

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Combined Nanoparticle Delivery of PARP and DNA-PK Inhibition for Multiple Myeloma

The Cytotoxic Effect of the PARP Inhibitor ABT-888 on Myeloproliferative Neoplasms

C75 Fatty Acid Synthesis (FAS) Inhibitor Has Potent Immunosuppressive Activity

In-Vitro and in-Vivo Synergistic Effect of Melphalan and Dual DNA Repair Inhibition in Multiple Myeloma

Dual DNA Damage Repair Inhibition Synergizes with Alkylator Chemotherapy for Myeloma and Acute Leukemia

Preclinical Study for the Use of Abatacept to Prevent Rejection of Allogeneic CD34+ Cells in a Xenograft Model

A Critical Role of Mir-9 in Myelopoesis and EVI1-Induced Leukemogenesis.

Methylation and Silencing of miRNA-124 In Hematopoietic Cells by EVI1

Preferential Nuclear Accumulation of JAK2V617F In CD34+ but Not Granulocytic, Megakaryocytic or Erythroid Cells of Patients with Philadelphia-Negative Myeloproliferative Neoplasia

EVI1 Interacts with and Represses RUNX1: A Novel Mechanism of Deregulated Hematopoiesis in EVI1-Positive Hematopoietic Cells.

AML1/MDS1/EVI1 Induces Essential Thrombocythemia in Mice Independently of Jak2 Mutations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only